Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this first-in-class alpha-emitting radiopharmaceutical underlies its favorable safety profile and low incidence of myelosuppression. In the pivotal phase 3 ALpharadin...

The present study was undertaken with a view of determining in a general way the effects of intravenous administration of radium upon the circulation and respiration. The problem was suggested to us by Dr. William J. Gies, under whose guidance a number of researches, dealing with the more extensive question of the action of radium upon animal and vegetable cells, have recently been carried on i...

Radium-223 is a first-in-class alpha particle-emitting radiopharmaceutical approved for the treatment of bone metastatic castration-resistant prostate cancer. Radium-223 is administered intravenously with no requirement for complex shielding and specifically targets areas of bone metastasis. In a randomized placebo-controlled Phase III study, treatment with radium-223 was shown to improve overa...

OBJECTIVE This open-label, non-randomized, phase I study examined the pharmacokinetics (PK) and radiation dosimetry of a single dose of radium-223 in Japanese patients with castration-resistant prostate cancer (CRPC) and bone metastases. METHODS Six male Japanese patients (mean age 72.5 years, range 65-79 years) with histologically or cytologically confirmed stage IV adenocarcinoma of the pro...

Bone metastases, which are commonly seen in patients with advanced cancers, are a major cause of skeletal events, disability, and death. Radium-223 dichloride (radium-223; Xofigo, formerly Alpharadin), a first-in-class, alpha-emitting radiopharmaceutical that selectively targets bone metastases with high-energy short-range alpha-particles, has been approved for the treatment of patients with ca...

milligram. As representatives in the British Empire "of the Radium Beige (Union Miniere du Haut Katanga), we would like to have an opportunity of correcting this statement. Previous to the discovery of the rich ores in the Belgian Congo, the standard price for radium element was $110 per milligram, and this price was reduced following the production of radium from the Congo ore to $70, equivale...

Saline waters from underground coal mines in Poland often contain natural radioactive isotopes, mainly 226Ra from the uranium decay series and 228Ra from the thorium series. More than 70% of the total amount of radium remains underground as radioactive deposits due to spontaneous co-precipitation or water treatment technologies, but several tens of MBq of 226Ra and even higher activity of 228Ra...

In 1936, almost 4 decades after the discovery of the x-ray and of radium, the German Röntgen Society erected a monument to commemorate all who had died as a consequence of exposure to x-rays or radium. George W.C. Kaye of the US National Physical Laboratory wrote the inscription: “To the röntgenologists and radiologists of all nations, doctors, physicists, chemists, technical workers, laborator...

Metastatic castration-resistant prostate cancer (mCRPC) frequently metastasizes to the bone, often resulting in painful skeletal events, reduced quality of life, and reduced survival. The beta-emitting radiopharmaceuticals strontium-89 and samarium-153 alleviated pain in mCRPC patients with widespread skeletal metastases and have been associated with myelotoxicity. Radium-223, a first-in-class ...

INTRODUCTION A number of drugs have been shown to extend life expectancy in castration-resistant prostate cancer (CRPC). Skeletal related events (SREs) secondary to bone metastases cause significant morbidity for men with CRPC. The α-emitting radiopharmaceutical radium-223 dichloride has been shown to improve overall survival, time to symptomatic skeletal events (SSEs) and quality of life in CR...